A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II/III
Latest Information Update: 27 Mar 2019
Price : $35 *
At a glance
- Drugs AL 335/odalasvir/simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 23 Mar 2018 Status changed from recruiting to discontinued.
- 06 Mar 2018 This trial has been completed in Spain (end of the trial:2018-01-31) as per European Clinical Trials Database record.